PIROXICAM

Search structure


Trade Names:	FELDENE PIROXICAM
Synonyms:	Brexidol CP-16,171 CP-16171 Feldene Feldene 20 Feldene p Flamatrol Kentene Larapam NSC-666076 Piroflam 10 Piroflam 20 Piroxicam Pirozip 10 Pirozip 20
Status:	Approved (1982)
Entry Type:	Small molecule
Molecule Category:	Parent
ATC:	M01AC01
UNII:	13T4O6VMAM

Structure


InChI Key	QYSPLQLAKJAUJT-UHFFFAOYSA-N
Smile	CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O
InChI	InChI=1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,19H,1H3,(H,16,17,20)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C15H13N3O4S
Molecular Weight	331.35
AlogP	1.58
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	2.0
Polar Surface Area	99.6
Molecular species	ACID
Aromatic Rings	2.0
Heavy Atoms	23.0

Pharmacology

Action	Mechanism of Action	Reference
INHIBITOR	Cyclooxygenase inhibitor	PubMed PubMed PubMed

	Primary Target
COX-1
COX-2

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Oxidoreductase	-	1300-85114	-	-	25-62
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	16-69

Metabolites

visNetwork

Indications

Mesh Heading	Maximum Phase	Mesh ID	Reference
Osteoarthritis	4	D010003	FDA
Tennis Elbow	2	D013716	ClinicalTrials
Osteoarthritis, Knee	2	D020370	ClinicalTrials
Renal Colic	1	D056844	ClinicalTrials

Related Entries

MCS

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend :

Indication

Mechanism of Action

Primary Target

Target Level

Scaffolds

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Side Effects from Label

Side Effects (PT)

Side effects	Relative Frequency (%)	Labels
Gastrointestinal disorders Abdominal discomfort	5.7
Gastrointestinal disorders Flatulence	5.2
Gastrointestinal disorders Nausea	4.8
Gastrointestinal disorders Abdominal pain	4.7
Gastrointestinal disorders Gastrointestinal pain	4.7
Cardiac disorders Dizziness	4.1
Gastrointestinal disorders Dyspepsia	4.1
Nervous system disorders Headache	4.1
Gastrointestinal disorders Constipation	3.8
Gastrointestinal disorders Diarrhoea	3.2
General disorders and administration site conditions Oedema	2.7
Skin and subcutaneous tissue disorders Dermatitis	2.4
Skin and subcutaneous tissue disorders Rash	2.4
Nervous system disorders Somnolence	2.1
Skin and subcutaneous tissue disorders Pruritus	1.1
Gastrointestinal disorders Stomatitis	1.0

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
Immune system disorders	21.2
General disorders and administration site conditions	12.67
Skin and subcutaneous tissue disorders	10.29
Gastrointestinal disorders	9.65
Nervous system disorders	6.04
Injury, poisoning and procedural complications	5.88
Vascular disorders	5.88
Musculoskeletal and connective tissue disorders	5.44
Cardiac disorders	3.0
Respiratory, thoracic and mediastinal disorders	2.9
Psychiatric disorders	2.58
Metabolism and nutrition disorders	2.33
Infections and infestations	2.24

Cross References

Resources	Reference
CAS NUMBER	36322-90-4
ChEBI	8249
ChEMBL	CHEMBL527
DrugBank	DB00554
DrugCentral	2210
EPA CompTox	DTXSID5021170
FDA SRS	13T4O6VMAM
Human Metabolome Database	HMDB0014694
Guide to Pharmacology	7273
KEGG	C01608
PubChem	54676228
SureChEMBL	SCHEMBL13462
ZINC	ZINC000051133897

CONTENTS